CLICK HERE FOR INVESTOR PORTAL
Hadean Ventures
Hadean Ventures
Hadean Ventures
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT/ESG
  • EVENTS
  • CAREERS
  • CONTACT

    @hadeanventures

  • All
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • Current companies
  • Exited companies
  • News
  • Uncategorized
  • Ribbon Bio and Syngoi Technologies Commence Strategic Collaboration to Advance Gene Therapies with Synthetic DNA

    by @hadeanventures on March 12, 2025

    Collaboration builds upon Syngoi’s synthetic DNA manufacturing capabilities and Ribbon’s algorithm-driven technology to produce pristine…

    Continue Reading
  • Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of Abliva AB (publ) and extends the acceptance period

    by @hadeanventures on February 25, 2025

    Pharming Technologies B.V. declares unconditional and completes the recommended cash offer to the shareholders of…

    Continue Reading
  • Neuro Event Labs Oy raises €2.0M investment for commercial expansion in Europe and US market entry of its AI-powered seizure detection device for epilepsy.

    by @hadeanventures on February 14, 2025

    Tampere, Finland – 12 February 2025: Neuro Event Labs Oy today announced it has raised…

    Continue Reading
  • Neuro Event Labs, Nelli® officially received European MDR (Medical Device Regulation) certification as a Class IIa medical device

    by @hadeanventures on December 20, 2024

    Great news from Neuro Event Labs Oy, as Nelli®, their AI-powered seizure detection and characterization…

    Continue Reading
  • TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001

    by @hadeanventures on December 19, 2024

    TargED Biopharmaceuticals doses first participant in Phase 1 clinical trial of TGD001, a groundbreaking thrombolytic…

    Continue Reading
  • ARTHEx Biotech Announces First Patient Dosed in Phase I-IIa ArthemiR™ Trial for Myotonic Dystrophy Type 1 (DM1)

    by @hadeanventures on October 18, 2024

      VALENCIA, Spain, Oct. 18, 2024 /PRNewswire/ — ARTHEx Biotech S.L., a clinical-stage biotechnology company focused on…

    Continue Reading
  • SciRhom Initiates Dosing in First-in-Man Clinical Study Evaluating theCompany’s Lead Development Program SR-878

    by @hadeanventures on October 17, 2024

    Transition into clinical-stage development marks a significant corporate and R&D milestone. Munich, Germany, October 17,…

    Continue Reading
  • Step Pharma announces first patient dosed in a phase 1 trial of dencatistat for patients with solid tumours

    by @hadeanventures on September 24, 2024

    Step Pharma, the world leader in CTPS1 inhibition for the targeted treatment of cancer, today…

    Continue Reading
  • Alex Therapeutics has signed an exclusive agreement with Navamedic

    by @hadeanventures on September 12, 2024

    Alex Therapeutics has signed an exclusive agreement with Navamedic for the development of a Companion…

    Continue Reading
  • SCIRHOM

    by @hadeanventures on August 5, 2024

    SciRhom GmbH is a German biotechnology company...

    Continue Reading
  • 1
  • 2
  • 3
  • 4
  • …
  • 8
  • 9
  • 10
  • →
  • HOME
  • TEAM
  • NEWS
  • PORTFOLIO
  • INVESTORS
  • IMPACT/ESG
  • EVENTS
  • CAREERS
  • CONTACT

What are you looking for?